Daewoong Pharmaceutical\'s Nabota botulinum toxin reached 228.9 billion won in 2025 sales (16.5% of total revenue) — continuing Korean pharmaceutical industry\'s significant pivot toward aesthetic medicine. With Easydew cosmetics surpassing 100 billion won cumulative sales and the NABOTA Master Class Spring 2026 bringing 74 healthcare professionals from 13 countries to Korea, the industry transformation continues. This news article examines the Korean pharma-aesthetic pivot.
Daewoong Nabota financial growth
2024-2025 performance
- 2024 sales: 186.4 billion won.
- 2024 revenue share: 14.7%.
- 2025 sales: 228.9 billion won.
- 2025 revenue share: 16.5%.
- Substantial growth trajectory.
Industry significance
- Aesthetic flagship revenue source.
- Pharmaceutical company transformation.
- Korean industry trend.
- Long-term competitive positioning.
NABOTA international
Jeuveau (US market)
- NABOTA marketed as Jeuveau in US.
- Same formula, different market.
- FDA-approved 2019.
- First Korean toxin in US.
- Industry milestone.
Global expansion
- Latin America emerging markets.
- Middle East expansion.
- Asia-Pacific presence.
- Continued international growth.
NABOTA Master Class Spring 2026
Global education program
- April 2026 hosted.
- 74 healthcare professionals.
- 13 countries represented.
- Industry leadership.
- Korean specialty showcase.
Educational focus
- High-dose treatment safety.
- Repetitive treatment protocols.
- Industry best practices.
- Comprehensive expertise.
Korean pharmaceutical industry pivot
Industry-wide trend
- Aesthetic > prescription drugs growth.
- Daewoong, Hugel, Medytox leadership.
- Industry transformation.
- Long-term competitive advantage.
Why the pivot
- Cosmetic margins higher.
- Korean specialty advantage.
- K-beauty global expansion.
- Industry maturation.
Easydew cosmetics
Daewoong cosmetics brand
- 100 billion won+ cumulative sales (July 2025).
- Daewoong\'s cosmetic flagship.
- Industry diversification.
- Long-term growth.
K-beauty integration
- Pharmaceutical-grade cosmetics.
- Korean industry leadership.
- International market.
- Industry credibility.
Korean botulinum toxin market
Market size
- 2023: USD 194.1 million.
- 10.4% CAGR projected 2024-2030.
- Substantial growth trajectory.
- Industry maturation.
Major Korean manufacturers
- Hugel (Letybo).
- Daewoong (Nabota/Jeuveau).
- Medytox (Innotox).
- PharmaResearch (Botulax).
- Industry diversity.
Industry implications
Korean cosmetic exports
- Continued international expansion.
- Industry maturation.
- K-beauty industry alignment.
- Long-term competitive advantage.
Pharma-cosmetic convergence
- Pharmaceutical companies cosmetic-focused.
- Industry transformation.
- Korean specialty leadership.
- Long-term direction.
For Korean cosmetic clinics
Domestic supply
- Multiple Korean toxin options.
- Cost-effective alternatives.
- Quality reputation.
- Industry support.
Premium service tier
- Premium clinics offering Daewoong products.
- Long-term clinic relationships.
- Comprehensive aesthetic services.
- Industry maturation.
For international patients
Daewoong product accessibility
- Authentic Korean Nabota at Korean prices.
- Substantial cost savings vs US.
- Authentic experience.
- Quality reputation.
Industry maturation
- Korean cosmetic medicine continued growth.
- Industry stability.
- Long-term care availability.
- Quality reputation.
Comparison with global leaders
Allergan/AbbVie (Botox)
- Global leader.
- Korean Daewoong competitor.
- Premium positioning.
- Industry standard.
Other Korean manufacturers
- Hugel global expansion competing.
- Multiple Korean players.
- Industry diversification.
- Long-term competition.
Industry challenges
Pricing pressure
- Cosmetics, toxins becoming profit drivers amid drug price cuts.
- Pharmaceutical industry adaptation.
- Strategic positioning.
- Long-term direction.
International competition
- Multiple international toxin manufacturers.
- Marketing investment needed.
- Industry positioning.
- Long-term strategy.
Industry outlook
Continued aesthetic pivot
- Korean pharma transformation continuing.
- Industry investment.
- International market expansion.
- Long-term competitive advantage.
K-aesthetic global influence
- K-content global success.
- K-beauty international.
- K-toxin global expansion.
- Industry alignment.
For prospective patients
Industry stability
- Korean industry strong.
- Long-term availability.
- Quality reputation maintained.
- Industry maturation.
Brand verification
- Multiple Korean options.
- Provider experience matters.
- Quality verification important.
- Long-term care planning.
The honest framing
Daewoong\'s NABOTA growth and Korean pharmaceutical industry\'s aesthetic pivot represents continued 2026 industry transformation — pharmaceutical companies pivoting from prescription drugs to cosmetics and toxins driven by margin advantages and K-beauty global expansion. The patients who benefit most access authentic Korean toxins at Korean prices through licensed providers, choose quality-emphasis providers, and maintain long-term care relationships. The Korean cosmetic medicine industry continues maturation with strong financial fundamentals from pharmaceutical-cosmetic convergence; the long-term outlook supports continued patient access and quality care delivery.